Induction of the Epstein-Barr virus latent membrane protein 2 antigen-specific cytotoxic T lymphocytes using human leukocyte antigen tetramer-based artificial antigen-presenting cells

Acta Biochimica et Biophysica Sinica

Volumn 38, Issue 3, 2006, Pages 157-163

  Lu, Xiao Ling ^a   Liang, Zhi Hui ^a   Zhang, Cai E ^a   Lu, Sheng Jun ^a   Weng, Xiu Fang ^a   Wu, Xiong Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Artificial antigen presenting cell; Cytotoxic T lymphocyte; Epstein Barr virus; Immunotherapy

Indexed keywords

EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; HLA A2 ANTIGEN; HLA ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MATRIX PROTEIN;

ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELL CULTURE; CHEMISTRY; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; HODGKIN DISEASE; HUMAN; IMMUNOLOGY; LEUKOCYTE; METABOLISM; NASOPHARYNX TUMOR; PATHOLOGY; VIRUS INFECTION;

ANTIGEN-PRESENTING CELLS; CD4-POSITIVE T-LYMPHOCYTES; EPSTEIN-BARR VIRUS INFECTIONS; HLA ANTIGENS; HLA-A2 ANTIGEN; HODGKIN DISEASE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTES; NASOPHARYNGEAL NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 33645003646     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1111/j.1745-7270.2006.00150.x     Document Type: Article

References (33)

1. Rooney CM Smith CA Ng CYC Loftin SK Sixbey JW Gan Y Srivastava DK et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients Blood 1998 92 1549 1555
2. Bollard CM Aguilar L Straathof KCM Gahn B Huls MH Rousseau A Sixbey J et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease J Exp Med 2004 12 1623 1633
3. Rooney CM Heslop HE Brenner MK. EBV specific CTL: A model for immune therapy Vox Sang 1998 2 497 498
4. Gottschalk S Heslop HE Roon CM. Treatment of Epstein-Barr virus-associated malignancies with specific T cells Adv Cancer Res 2002 84 175 201
5. Straathof KCM Bollard CM Popat U Huls MH Lopez T Morriss MC Gresik MV et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes Blood 2005 105 1898 1904
6. Bollard CM Straathof KCM Huls MH Leen A Lacuesta K Davis A Gottschalk S et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease J Immunother 2004 27 317 327
7. Redchenko IV Rickinson AB. Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells J Virol 1999 73 334 342
8. Su Z Peluso MV Raffegerst SH Schendel DJ Roskrow MA. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease Eur J Immunol 2001 31 947 958
9. van Rensen AJ Wauben MH Grosfeld-Stulemeyer MC van Eden W Crommelin DJ. Liposomes with incorporated MHC class II/peptide complexes as antigen presenting vesicles for specific T cell activation Pharm Res 1999 16 198 204
10. Prakken B Wauben M Genini D Samodal R Barnett J Mendivil A Leoni L et al. Artificial antigen-presenting cells as a tool to exploit the immune 'synapse' Nat Med 2000 6 1406 1410
11. Curtsinger J Deeths MJ Pease P Mescher MF. Artificial cell surface constructs for studying receptor-ligand contributions to lymphocyte activation J Immunol Methods 1997 209 47 57
12. Tham EL Jensen PL Mescher MF. Activation of antigen-specific T cells by artificial cell constructs having immobilized multimeric peptide-class I complexes and recombinant B7-Fc proteins J Immunol Methods 2001 249 111 119
13. Maus MV Riley JL Kwok WW Nepom GT June CH. HLA tetramer-based artificial antigen presenting cells for stimulation of CD4+ T cells Clin Immunol 2003 106 16 22
14. Oelke M Maus MV Didiano D June CH Mackensen A Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells Nat Med 2003 9 619 624
15. Murray PG Constandinou CM Crocker J Young LS Ambinder RF. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease Blood 1998 92 2477 2483
16. Valmori D Pittet MJ Vonarbourg C Rimoldi D Lienard D Speiser D Dunbar R et al. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376 Cancer Res 1999 59 4050 4055
17. Parker KC Bednarek MA Hull LK Utz U Cunningham B Zweerink HJ Biddison WE et al. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2 J Immunol 1992 149 3580 3587
18. Altman JD Moss PA Goulder PJ Barouch DH McHeyzer-Williams MG Bell JI McMichael AJ et al. Phenotypic analysis of antigen-specific T lymphocytes Science 1996 274 94 96
19. Rees W Bender J Teague TK Kedl RM Crawford F Marrack P Kappler J. An inverse relationship between T cell receptor affinity and antigen dose during CD4+ T cell responses in vivo and in vitro Proc Natl Acad Sci USA 1999 96 9781 9786
20. Qian L Qian GX. In vivo CTL immunity can be elicited by OVA-linker-β2m fusion protein Acta Biochim Biophys Sin 2002 34 547 552
21. Maziarz RT Fraser J Srominger JL Burakoff SJ. The human HLA-specific monoclonal antibody W6/32 recognizes a discontinuous epitope within the α2 domain of murine H-2Db Immunogenetics 1986 249 206 208
22. Melief CJ Kast WM. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes Immunol Rev 1995 145 167 177
23. Rammensee HG Friede T Stevanovic S. MHC ligands and peptide motifs: First listing Immunogenetics 1995 41 178 228
24. Paczesny S Banchereau J Wittkowski KM Saracino G Fay J Palucka AK. Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells J Exp Med 2004 199 1503 1511
25. Hirschowitz EA Foody T Kryscio R Dickson L Sturgill J Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer J Clin Oncol 2004 22 2808 2815
26. Oosten LE Blokland E van Halteren AG Curtsinger J Mescher MF Falkenburg JH Mutis T et al. Artificial antigen-presenting constructs efficiently stimulate minor histocompatibility antigen-specific cytotoxic T lymphocytes Blood 2004 104 224 226
27. Oelke M Schneck JP. HLA-Ig-based artificial antigen-presenting cells: Setting the terms of engagement Clin Immunol 2004 110 243 251
28. Salter RD Howell DN Gresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids Immunogenetics 1985 21 235 246
29. Oelke M Moehrle U Chen JL Behringer D Cerundolo V Lindemann A Mackensen A. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy Clin Cancer Res 2000 6 1997 2005
30. Salgaller ML Lodge PA Mclean JG Tjoa BA Loftus DJ Ragde H Kenny GM et al. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA) Prostate 1998 35 144 151
31. Walunas TL Bakker CY Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation J Exp Med 1996 183 2541 2550
32. Walunas TL Lenschow DJ Bakker CY Linsley PS Freeman GJ Green JM Thompson CB et al. CTLA-4 can function as a negative regulator of T cell activation Immunity 1994 1 405 413
33. Latouche JB Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells Nat Biotechnol 2000 18 405 409